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Since the beginning of this century, we have been observing
increasingly rapid diffusion among Enterobacteriaceae of
extended-spectrum b-lactamases (ESBLs), mostly of the CTX
type and mostly in Escherichia coli [1]. This phenomenon has
run out of control within just 10 years, and the outbreak is
now internationally identiﬁed as being, in particular, a source
of community-acquired infections.
In this context of multiresistance, the increasing number of
carbapenemase-producing Enterobacteriacae is worrying,
because carbapenems represent the last line of antibiotics that
are still effective for treating many enterobacterial infections
[2,3]. Although the hydrolytic proﬁle of carbapenemases
(mostly KPC, OXA-48, IMP, VIM, and NDM) is somewhat vari-
able, all of them hydrolyse at least carbapenems [4–6]. The
corresponding genes may be considered as markers of multi-
drug resistance—or even pandrug resistance—in speciﬁc areas
in the world, as they are often found together with genes con-
ferring resistance to most b-lactams, aminoglycosides, and ﬂu-
oroquinolones. All of these genes are easily transferable within
Enterobacteriaceae, because they are plasmid-borne.
If one considers the carbapenemase type and the host
bacterial species, so far KPC, IMP and VIM seem to have
been mostly identiﬁed in the main nosocomial pathogen,
which is Klebsiella pneumoniae [4–6]. By contrast, in the case
of carbapenemases of the NDM and OXA-48 types, both
K. pneumoniae and E. coli can be regarded as sources of both
nosocomial and community-acquired infections [4–6].
Identiﬁcation of carbapenemase producers in Enterobacte-
riacae is becoming the major issue among antibiotic resis-
tance problems worldwide, and in particular in Europe, for
the following reasons:
• Enterobacteriaceae (E. coli in particular) are the source of
the most frequent infections in humans, and the mortality
rate is high.
• The number of carbapenemase producers is still limited in
many countries in the world. Thus, controlling their spread
in hospital settings is still both possible and worthwhile.
• The therapeutic possibilities for infections caused by carba-
penemase producers are very limited [2,4]. Identiﬁcation
of the multidrug resistance pattern of these strains is
therefore of primary importance.
The possibility of spread of carbapenemase producers is
important. It will possibly mirror what has been extensively
described for ESBL producers as a source of nosocomial
infections since the 1980s. There are many reasons to
believe that carbapenemase-expressing K. pneumoniae and
Enterobacter spp. will act as the main source of nosocomial
infections, as already reported in the case of ESBL produc-
ers. Screening of carriers is of fundamental importance, and
should ﬁrst be proposed for the most vulnerable patients
such as immunocompromised patients and those hospitalized
in units at high risk of colonization by multidrug-resistant
bacteria (such as intensive-care units). In addition, it should
be considered that carbapenemase-producing E. coli (mostly
harbouring enzymes of the NDM and OXA-48 types) may
spread at a lower rate but become rapidly uncontrollable in
community settings, as observed for CTX-M producers
among E. coli.
The present CMI issue is largely based on a conference
sponsored by the ESCMID on carbapenemases held in Paris
at the end of 2011. It will detail the spread of carbapenem-
ase producers in Europe [7], summarize the current identiﬁ-
cation techniques and the methods for preventing their
spread in hospital settings [8], and report infections and dis-
cuss therapeutic strategies [9]. We believe that these
updates could be particularly useful for both clinical microbi-
ologists and infectious diseases physicians, as carbapenem
resistance is rapidly becoming the main antibiotic resistance
issue worldwide.
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